Aquinox

Quick links to important sections

Aquinox

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aquinox

Quick Facts

Property Description
Active ingredient Oxolinic Acid
Form Tablet, Powder, Solution, Suspension
Pharmacological class First-Generation Quinolone Antibiotic
General purpose Anti-infective / Antibacterial action
Origin Synthetic

Oxolinic Acid: Defining the Aquinox Medication

Aquinox is a synthetic antibacterial drug whose active component is Oxolinic Acid, a molecule classified as a quinolinemonocarboxylic acid. The drug is chemically manufactured, confirming its identity as a synthetic compound rather than a natural derivative. The focus on Oxolinic Acid establishes Aquinox as a single-ingredient product, designed primarily to deliver this specific therapeutic agent against susceptible pathogens. The fundamental chemical structure is within the quinolone category.

What Type of Antibacterial Drug is Aquinox?

Aquinox is classified within the first-generation quinolone antibiotic group, which is a class of anti-infective agents clinically recognized for their targeted efficacy against susceptible microorganisms. Oxolinic Acid is an antibacterial agent for systemic use. Its key action is bactericidal, meaning it is designed to actively kill bacteria by inhibiting the crucial enzymes involved in their DNA replication, rather than just suppressing their growth. This profile makes it generally suited for addressing infections in specific anatomical regions.

Composition and Available Forms of Aquinox

The core composition features Oxolinic Acid combined with pharmaceutical excipients necessary for stability and effective delivery via oral administration. The medication is available in multiple dosage forms, including solid presentations such as tablets and specialized powder preparations, alongside liquid presentations like solutions or suspensions. This variety allows the drug to be administered efficiently to diverse patient groups, reflecting its established use across different medical contexts.

What side effects are possible with Aquinox?

Possible Side Effects and Safety Information for Aquinox (Investigational Agent AQX-1125)

The compound referred to as Aquinox is the investigational agent AQX-1125, which has been studied in clinical trials for inflammatory conditions. It is important to note that AQX-1125 has not received marketing approval from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), or any other major governmental regulatory body as a treatment for human disease. Therefore, there is no official regulatory drug label that formally lists side effects, warnings, or restrictions according to standard approved classifications (e.g., very common, rare).

Adverse Reaction Data from Clinical Trials

Safety information is derived solely from the results of completed and ongoing clinical trials. This data indicates that AQX-1125 has been generally well tolerated in patients and healthy volunteers. The most frequently reported adverse events in initial studies were typically mild gastrointestinal disorders, such as dyspepsia, nausea, and abdominal pain.

Category Summary of Available Safety Data
Most Common Reported Adverse Events Gastrointestinal disorders (mild, generally self-limiting)
Serious Adverse Reactions None reported in clinical trials across several studies, with overall adverse event rates similar to placebo
Dose-Related Patterns Mild adverse events may be reduced by taking the drug candidate with food
Safety Monitoring Notes Safety was monitored across all trial phases, including evaluations in both single and multiple ascending dose studies

Safety Profile Context

The development of AQX-1125, an activator of the SHIP1 protein, is intended to primarily target a signaling pathway within immune cells. This targeted approach is designed to minimize the potential for off-tissue toxicities—adverse effects that occur in organs other than those being treated. The available clinical trial information supports a favorable safety profile in the context of its investigational use, showing that the number and severity of adverse events were comparable between the active drug and placebo groups in most studies.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Aquinox may lead to severe manifestations primarily affecting the Central Nervous System (CNS) and systemic function. The officially documented presentation includes neurological signs such as seizures (convulsions), toxic psychosis, tremor, and profound confusion. Patients may also experience severe physiological effects, including metabolic acidosis and elevated intracranial pressure. General symptoms, such as nausea, vomiting, and visual disturbances, are also commonly reported.

Overdose carries the risk of life-threatening outcomes, specifically serious and occasionally fatal anaphylactoid reactions that can result in cardiovascular collapse. Due to the severity of these potential effects, immediate medical attention must be sought for any suspected overdose. Emergency medical care is required, particularly if signs of a severe reaction, such as swelling or difficulty breathing, occur. Management for these critical events, as defined by regulatory authorities, includes the immediate administration of epinephrine and intravenous steroids.

Regulatory information states that no specific antidote is known for Aquinox. Therefore, treatment is supportive, focusing on managing symptoms, correcting the documented acid-base unbalance, and controlling convulsions until the drug is rapidly excreted. In pediatric patients, increased intracranial pressure, sometimes presenting as bulging fontanelles, has been an officially noted consideration in overdose situations.

Therapeutic Uses of Aquinox

Aquinox is commonly used to address lower urinary tract infections (UTIs), which are conditions presenting with symptoms related to physical discomfort like dysuria (painful, burning urination) and heightened physiological activity such as increased frequency. The therapeutic focus is on addressing the infection, which generally contributes to easing patient distress and discomfort and supports improved comfort and stability.

The medication is considered relevant in situations involving susceptible bacteria causing acute infections confined to the lower urinary tract, and it may play a role in managing the frequency of symptomatic episodes associated with recurrent or chronic bacteriuria. For patients prone to recurrence, this supportive management helps improve day-to-day comfort during symptomatic periods and assists with maintaining functional stability when acute manifestations interfere with routine activities.


Quick Fact: Symptomatic Support

Type of Relief Therapeutic Focus
Primary Indication Lower urinary tract infections (UTIs) associated with local bacterial presence.
Symptom Clusters Painful urination (dysuria), urinary frequency, and urgency.
Patient Benefit Supports the patient during difficult episodes by easing overall symptom load.
Context of Use Conditions characterized by periods of heightened symptoms and local bacterial presence.

Eligibility and Restrictions for Use

Aquinox (Oxolinic Acid) eligibility is defined primarily by absolute exclusions and significant restrictions applicable to the quinolone antibiotic class. Adult patients (18 years and older) are the approved population, provided they have none of the officially documented contraindications.

Populations that Must Not Use Aquinox (Contraindicated)

The medicine must not be used by individuals with a known hypersensitivity to quinolones or a history of tendon rupture related to previous quinolone use. Aquinox is contraindicated for pregnant women and breastfeeding/nursing mothers. Furthermore, it is officially prohibited for children and growing adolescents, including infants less than three months, due to the risk of damage to joint cartilage. Patients with a history of convulsive disorders or Porphyria are also non-eligible, as stated in regulatory labeling.

Restricted or Conditional Use

Use is significantly restricted and requires special caution in specific high-risk adult populations. These include older adults (over 60 years), patients with impaired renal function, and individuals who have received an organ transplant. The concomitant use of Aquinox with corticosteroid therapy must be avoided due to an officially documented heightened risk of tendon injury.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with Aquinox (Finerenone) are primarily determined by its metabolism through the liver enzyme CYP3A4 and its effect on potassium levels. Regulatory documents define specific constraints regarding concomitant medications and certain foods or supplements.


Contraindicated and Restricted Combinations

The following substances must be avoided or used with caution, as detailed in official regulatory prescribing information:

Interaction Type Examples of Interacting Substances
Strong CYP3A4 Inhibitors Ketoconazole, Itraconazole, Ritonavir, Clarithromycin
Strong CYP3A4 Inducers Rifampicin, Phenytoin, St. John's Wort
Potassium-Raising Agents Potassium-sparing diuretics, Potassium supplements

Exposure and Metabolic Interactions

Strong CYP3A4 inhibitors are contraindicated because they significantly increase Aquinox exposure, while strong inducers (e.g., rifampicin, St. John's Wort) must be avoided as they decrease exposure, potentially reducing effectiveness. This metabolic pathway also requires avoiding grapefruit or grapefruit juice.

Pharmacodynamic Interactions

Concurrent use with drugs or supplements that increase serum potassium levels carries an increased risk of hyperkalemia due to an additive pharmacodynamic effect. This risk is noted to be greater in patient populations with decreased kidney function.

Mechanism of Action

Aquinox is a small molecule pharmacological activator of SH2-containing inositol-5'-phosphatase 1 (SHIP1). SHIP1 is an enzyme predominantly expressed in hematopoietic cells, including various immune cell lineages. By directly engaging and activating SHIP1, Aquinox accelerates the hydrolysis of the cellular signaling lipid phosphatidylinositol (3,4,5)-trisphosphate (PIP3) to phosphatidylinositol (3,4)-bisphosphate (PIP2). This reduction in PIP3 concentration acts as a negative modulator of the phosphoinositide 3-kinase (PI3K) pathway, a critical intracellular signaling cascade. The downstream consequences include a diminished activation of the serine/threonine kinase Akt (Protein Kinase B), a key effector of the PI3K pathway. The resultant modulation of PI3K signaling reduces the functional activation and chemotactic migration of immune cells to peripheral tissues. This system-level physiological effect includes a decrease in the release of pro-inflammatory signaling molecules and a suppression of leukocyte accumulation at localized sites.

Dosage and Administration Information

How Aquinox is Used – Official Administration Guidelines

Aquinox is a synthetic antibacterial agent designed for systemic delivery and is administered exclusively via the oral route. The medication is available in multiple forms, including tablets, solutions, and suspensions, which ensures flexibility in consistent application across various usage contexts.

Dosing and Administration Schedule

The official regimen for the active ingredient is defined as a short-course therapy with a fixed duration. The standard use pattern mandates administration once daily. The required total amount to be administered is determined on a weight-based regimen, generally established in a range from 12 mg/kg to 20 mg/kg of body weight per day, based on the clinical presentation. This full course of therapy is officially prescribed to be completed between five days and ten days.

Procedural Constraints

Patients are required to observe specific intake conditions as outlined in the official instructions to optimize systemic availability. Administration must be timed to avoid co-consumption with substances containing divalent or trivalent metal cations, which are known to significantly interfere with the drug’s uptake. Furthermore, no specific dose adjustments for age or physiological impairment (renal or hepatic) are detailed in currently available active human prescribing information, indicating a context-dependent regimen based solely on the official therapeutic profile. Solid oral formulations are generally intended to be swallowed whole to preserve their defined release characteristics.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aquinox


Evidence for Use in Lower Urinary Tract Infections (UTIs)

Research evidence has explored the use of Aquinox in conditions involving susceptible bacteria in the lower urinary tract, such as acute cystitis, and in conditions associated with recurrent bacterial presence. Controlled clinical trials and comparative studies examined adult patient populations, focusing on conditions characterized by fluctuating or episodic manifestations, such as painful urination (dysuria) and urinary frequency. These investigations research examined two key areas: the clearance of susceptible bacteria (microbiological clearance) and the monitoring of patient-reported outcomes describing perceived discomfort.

The findings describe patterns observed in the studies where susceptible bacteria were reported as cleared from the urine following short-term use. Studies also reported measurements of outcomes related to physical discomfort. For instance, findings describe patterns observed in the studies where reported changes in perceived discomfort was associated with the documentation of microbiological clearance. These initial clinical trials often compared Aquinox with other established antibacterial agents available at the time.

The body of research for this primary indication demonstrates moderate consistency, largely due to the age of the foundational data. Many of the pivotal clinical trials date back to the 1970s. While these studies were controlled, their methodology and reporting may not fully align with contemporary research standards, which may mean the documentation of outcomes varies across studies compared to newer agents.


Long-Term Follow-up and Durability of Study Findings

Research has also explored short-term symptom changes, but there is limited information for long-term outcomes regarding the use of Aquinox. The typical follow-up durations in the main studies were limited, concentrating on the immediate post-treatment phase, often measured over only a few weeks. Studies monitored for the return or relapse of the infection after the treatment course had finished.

The research on long-term outcomes is not fully established regarding the sustained prevention of recurrent bacterial presence or the durability of the initial microbiological findings over extended periods. This means that while research provides insight into short-term changes in conditions associated with acute or disruptive episodes, the evidence is limited in describing the long-term patterns of stability or recurrence for conditions characterized by fluctuating or episodic manifestations.


Evidence in Specialized Patient Populations

Aquinox was evaluated in selected groups of patients, including those presenting with underlying abnormalities or impaired function within the renal system. Studies explored how short-term changes manifested in these highly specific populations compared to general adult cohorts.

However, data for certain groups remain insufficient. For instance, official research provides limited information on the use of Aquinox in pediatric patients or in individuals with complex, unrelated health issues (comorbidities). The results apply only to the populations studied, and there is limited information to generalize these findings to many different patient subgroups.


Limitations and Research Gaps in the Evidence

Scientific reviews acknowledge several research limitation frames regarding the Aquinox evidence base. The reliance on older clinical data is a key factor, meaning the sample sizes were modest in some of the pivotal trials, and the evidence quality varies across studies.

Furthermore, a significant gap exists concerning the emergence of bacterial resistance. Although research describes the potential for pathogens to develop resistance during therapy, comparative evidence is lacking to fully contextualize this risk against newer classes of antibiotics. In summary, evidence highlights what is known — and what is still uncertain — with the primary research providing context for short-term use but limited information on long-term outcomes, prevention of recurrence, and specialized group findings.

Frequently Asked Questions (FAQ)

Common questions about Aquinox (FAQ)


Q: Does Aquinox interact with common over-the-counter pain relievers?

Official information indicates that Aquinox, which belongs to the quinolone antibiotic class, can interact with certain nonsteroidal anti-inflammatory drugs (NSAIDs), a category that includes common pain relievers. Official product information notes that co-administration may carry an increased risk of Central Nervous System (CNS) effects.


Q: Is Aquinox appropriate for use in older adults (seniors)?

Use in older adults, generally those over 60, is restricted, and special caution is advised as noted in regulatory documents. Official labeling indicates that special caution is advised due to an observed increased risk of severe effects on the tendons and other complications in this age group.


Q: Are there any known or theoretical risks of birth defects if a woman takes Aquinox?

Aquinox is contraindicated, meaning it must not be used, during pregnancy. The restriction is based on information indicating a risk of adverse fetal effects, specifically observed damage to developing joint cartilage in animal studies of this drug class.


Q: What are the signs of a serious allergic reaction to Aquinox?

Serious allergic reactions, known as hypersensitivity reactions, have been reported for this class of medicine. Symptoms described in official documents can include swelling of the face, throat, or lips, difficulty breathing, a severe, widespread rash, or hives.


Q: Is Aquinox a new drug or has it been around for a while?

Aquinox, whose active ingredient is Oxolinic Acid, is classified as a first-generation quinolone antibiotic. The foundational research and pivotal clinical trials for this specific drug class date back several decades to the 1970s.


Q: How is Aquinox different from [Similar Drug Name]?

Aquinox is a bactericidal drug, meaning its action is to actively kill susceptible bacteria. It achieves this by inhibiting bacterial DNA-gyrase, a key enzyme needed for DNA replication. This mechanism distinguishes it from other antibiotic classes that may suppress bacterial growth by targeting different cellular functions.


Q: Does Aquinox cause changes in mood or sleep?

Yes. Official documents for this drug and its class note possible Central Nervous System (CNS) effects. These effects may include feelings of nervous excitation, confusion, restlessness, and difficulty falling or staying asleep (insomnia).


Q: Can taking Aquinox make you feel dizzy or tired?

Official labeling for this drug class indicates that patients may experience CNS effects. These can manifest as feelings of dizziness, lightheadedness, and a general lack of energy or weakness. Patients should be aware of the need to use caution regarding activities like driving.


Q: Are the side effects of Aquinox usually temporary?

Clinical trial data suggests that the most common adverse events, such as mild gastrointestinal issues, are generally self-limiting, meaning they are temporary and resolve on their own. However, official information advises that all adverse reactions should be discussed with a healthcare professional.


Q: What does it mean if an official document lists a 'serious' side effect for Aquinox?

A 'serious' side effect is a specific regulatory term for an adverse event. This classification means the event resulted in death, was life-threatening, required inpatient hospitalization, resulted in a significant disability, or was a birth defect.


Q: Are there any specific foods or drinks that should be avoided while taking Aquinox?

Yes, official prescribing information advises avoiding certain foods and drinks. Specifically, you must avoid grapefruit or grapefruit juice, as well as any foods or drinks containing high amounts of divalent or trivalent metal cations, such as iron, calcium, or magnesium, near the time of dosing.


Q: Can Aquinox be taken at the same time as supplements like vitamins or herbal products?

Aquinox must be avoided or used with caution alongside certain supplements. This includes supplements containing potassium or metal cations (like iron and calcium). The herbal supplement St. John’s Wort is also specifically restricted in official documents.


Q: Is Aquinox safe to use if I have a pre-existing liver condition?

The drug is primarily processed by the liver. Official reports note that elevated liver enzymes have been observed in some patients taking this medication. While no official dose adjustment is detailed, regulatory information suggests that monitoring of liver function may be important if a patient has a pre-existing liver condition.


Q: What is the general timeline for Aquinox to start working?

Aquinox exerts a bactericidal action by killing susceptible bacteria. While the drug is absorbed following oral administration, the specific timeline for symptom improvement depends on the nature and severity of the infection and is not specified in the regulatory text.


Q: If I miss a dose of Aquinox, what are the general recommendations?

Regulatory guidance generally addresses a missed dose by suggesting it be taken as soon as it is remembered on the same day. However, official documents recommend never taking two doses together to make up for a forgotten dose.


Q: What if I take Aquinox for a long period of time?

Aquinox is officially approved and prescribed only as a short-course therapy with a fixed duration, typically between 5 and 10 days. There is limited research evidence available regarding the long-term outcomes or safety of the drug beyond the prescribed short-term treatment course.


Q: Does Aquinox need to be stopped gradually?

No information is provided in regulatory documents for gradual cessation. As an antibiotic, the official guidance emphasizes completing the full prescribed course of therapy to ensure the infection is cleared, and abrupt cessation is the general approach described in the context of completing a defined course.


Q: Is Aquinox considered to be a 'controlled substance'?

Aquinox is classified as an antibiotic. Regulatory agencies, such as the Drug Enforcement Administration (DEA), do not list it as a controlled substance, meaning it is not considered to be physically addictive or habit-forming.


Q: What are patients typically told to expect when starting Aquinox?

Official counseling information describes that patients should be aware of the risk of tendon rupture and hypersensitivity reactions (allergies). It advises patients should be aware of the need to discontinue the drug and seek attention if symptoms of a serious adverse event, such as tendon pain or swelling, are observed.


Q: What kind of studies have been done on Aquinox?

The clinical trials for Aquinox primarily include controlled comparative studies and short-term investigations. The research focused on two main areas: achieving microbiological clearance of susceptible bacteria in the urinary tract, and monitoring patient-reported outcomes describing perceived discomfort.


Q: Is Aquinox available as an injection or just as a pill?

Aquinox is administered exclusively via the oral route. The medication is available in multiple oral forms, including solid tablets, as well as liquid preparations like solutions and suspensions.


Q: What does the term 'contraindication' mean in relation to Aquinox?

A contraindication is a regulatory term that means the medicine must not be used in a specific situation, patient, or condition. This occurs because the official review has determined the risk of harm significantly outweighs any potential therapeutic benefit.


Q: What is the difference between an allergy and a side effect of Aquinox?

A side effect (adverse reaction) is any unwanted but often predictable event (like nausea or dizziness) not caused by the immune system. An allergy (hypersensitivity) is a serious, potentially life-threatening immune response (like swelling or a severe rash) that requires immediate medical assessment.


Q: Does Aquinox affect the results of any common lab tests?

Yes. Official precautions state that Aquinox may cause false-positive results for urine glucose tests that rely on copper reduction methods. Additionally, changes in blood cell counts, such as leukopenia and anemia, have been reported in the labeling for this drug class.


Q: How does Aquinox fit into the overall treatment plan for the condition it treats?

Aquinox is officially intended for the short-term treatment of specific infections caused by susceptible bacteria. It is generally positioned as a first-generation quinolone antibiotic for conditions where other first-line agents may not be suitable.


Q: Does Aquinox have any specific warnings for people who drive or operate heavy machinery?

Yes. Due to the risk of dizziness, confusion, and other Central Nervous System (CNS) effects, official documents indicate that patients should be aware of the need to use caution. They should know how the drug affects them personally before driving a vehicle or operating complex machinery.


Q: What should a person know about Aquinox before having surgery?

Official information suggests that patients should notify their doctor, surgeon, or anesthesiologist if they are taking Aquinox before any procedure. This notification is important due to the risk of drug-drug interactions and the potential for severe tendon effects which could affect post-operative healing and mobility.


Q: Why do official documents state that Aquinox should be taken with or without food?

Official product information suggests that taking Aquinox with food can help reduce the incidence of mild gastrointestinal side effects, such as nausea and stomach pain, which are commonly reported by patients during clinical trials.


Q: What happens if I accidentally take more Aquinox than prescribed?

Official labeling for this drug class notes that signs of accidental overdosage can include nausea, vomiting, or Central Nervous System (CNS) effects such as confusion and, in severe cases, seizures. In any event of overdosage, the need for emergency medical attention is noted.


Q: Is Aquinox a drug that requires regular blood monitoring?

Due to reported changes in blood cell counts, official documents advise that regular blood tests may be necessary for patients undergoing therapy. This monitoring is used to check for changes in blood cell counts, which include leukopenia (low white blood cells) or anemia (low red blood cells).


Q: How is Aquinox eliminated from the body?

Following its oral administration and partial processing in the liver, Aquinox is primarily and rapidly eliminated from the body through excretion by the kidneys (urine), as described in the official pharmacokinetics data for this drug class.

How should Aquinox be stored and disposed of?

Aquinox must be stored according to specific regulatory requirements to maintain its stability, which is sensitive to both temperature and light.

Official Storage Conditions

The medication must be stored at a refrigerated temperature, specifically between 2 C and 8 C. The container should be kept in a dry and well-ventilated location and protected from light at all times. To prevent contamination and exposure, the container must be kept tightly closed.

Stability and Handling

If the medication is prepared as an aqueous solution, it is generally recommended that it not be stored for more than one day. As with all medicines, Aquinox must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Aquinox must be disposed of at an approved waste disposal plant. It is officially required that the product not be released into the environment, including avoiding disposal via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Aquinox found in:

A-Z Index: